Barry J. Goldstein, M.D., Ph.D., has been appointed vice president and global therapeutic area head at Covance’s expanded Cardiovascular, Metabolic, Endocrine and Renal unit of the Clinical Development Services business. Dr. Goldstein will join the Medical & Scientific Affairs leadership team and will be based in Princeton, NJ.
Dr. Goldstein joins the company from Merck, where he served as vice president in Clinical Research and therapeutic area head for diabetes and endocrinology. He also managed Merck’s Phase II-IV clinical development team for a portfolio including diabetes, obesity, osteoporosis, and women’s health, and provided input on proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, lifecycle management activities, and pharmacovigilance and post-marketing studies.
“Barry brings significant endocrinology, metabolism and broad drug development experience to complement our existing cardiovascular expertise at Covance,” said Ken Somberg, chief medical officer and vice president, Clinical Development Services. “Barry is a noted leader in the field of diabetes mellitus and endocrinology. His leadership will help us expand our strategic vision in these key therapeutic areas, as well as provide critical scientific insight to our colleagues and our clients throughout the biopharmaceutical industry.”